甲状腺未分化癌的遗传学改变研究进展

摘要
图/表
参考文献(33)
相关文章 (9)

全文: PDF (0 KB) HTML (45 KB)
输出: BibTeX | EndNote (RIS)

摘要甲状腺未分化癌是一种恶性程度很高的肿瘤，区别于分化型甲状腺癌，常规的手术、放疗及化疗治疗效果较差。随着甲状腺未分化癌分子发病机制的不断研究，许多遗传学改变都被认为参与了甲状腺未分化癌发生、发展的过程，为甲状腺未分化癌的分子靶向治疗提供了新的可能。本文将介绍与甲状腺未分化癌发病相关的遗传学改变的研究进展，主要包括RAS/RAF/MAPK/ERK信号通路和PI3K/Akt mTOR信号通路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵佳正

关键词 ：甲状腺未分化癌, 分子机制, 基因

Abstract：As a highly malignant tumor,anaplastic thyroid carcinoma is different from differentiated thyroid cancer, conventionalsurgery,radiotherapy and chemotherapy can achieve poorresults in the treatmentofthyroid undifferentiated carcinoma.With the unceasing research on molecular pathogenesis of anaplastic thyroid carcinoma, many genetic changes are thought to be involved in the development process of anaplastic thyroid carcinoma and to provide a new possibility for molecular targeted treatment of thyroid undifferentiated carcinoma.In this paper,the research progress of the genetic changes related to the pathogenesis of anaplastic thyroid carcinoma is introduced, including RAS/RAF/MAPK/ERK signaling pathway and PI3K/Akt mTOR signaling pathway.

Key words： Anaplastic thyroid carcinoma Molecular mechanism Gene

作者简介: 赵佳正（1984-），男，临床医学博士，主治医师，主要从事甲状腺、喉、下咽等头颈肿瘤的研究工作

引用本文:

赵佳正. 甲状腺未分化癌的遗传学改变研究进展[J]. 中国当代医药, 2017, 24(12): 16-19.
ZHAO Jia-zheng. Research progress on genetic changes of anaplastic thyroid carcinoma. 中国当代医药, 2017, 24(12): 16-19.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I12/16

[2]	冯影，高明.94例甲状腺未分化癌临床分析[J].天津医科大学学报，2008，14（2）：207-209.
[1]	Haugen BR，Alexander EK，Bible KC，et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer：the AmericanThyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid，2016，26（1）：1-133.
[3]	Smallridge RC，Ain KB，Asa SL，et al.American thyroid association guidelines for management of patients with anaplastic thyroid cancer[J].Thyroid，2012，22（11）：1104-1139.
[4]	Bisof V，Rakusic Z，Despot M.Treatment of patients with anaplastic thyroid cancer during the last 20 years：whether any progress has been made?[J].Eur Arch Otorhinolaryngol，2015，272（7）：1553-1567.
[5]	Xu B，Ghossein R.Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma[J].Endocr Pathol，2016，27（3）：205-212.
[6]	Lennon P，Deady S，Healy ML，et al.Anaplastic thyroid carcinoma：failure of conventional therapy but hope of targeted therapy[J].Head Neck，2016，38（1）：E1122-E1129.
[7]	Santarpia L，El-Naggar AK，Cote GJ，et al.Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer[J].J Clin Endocrinol Metab，2008，93（1）：278-284.
[8]	Gupta N，Dasyam AK，Carty SE，et al.RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicularpattern cancers[J].J Clin Endocrinol Metab，2013，98（1），E914-E922.
[9]	Basolo F，Pisaturo F，Pollina LE，et al.N-ras mutation in poorly differentiated thyroid carcinomas：correlation with bone metastases and inverse correlation to thyroglobulin expression[J].Thyroid，2000，10（1）：19-23.
[10]	Howell GM，Hodak SP，Yip L.RAS mutations in thyroid cancer[J].Oncologist，2013，18（2）：926-932.
[11]	Rushton S，Burghel G，Wallace A，et al.Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma[J].Histopathology，2016，69（2）：524-526.
[12]	Riesco-Eizaguirre G，Rodríguez I，De la Vieja A，et al.The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer[J].Cancer Res，2009，69（21）：8317-8325.
[13]	Lim AM，Taylor GR，Fellowes A，et al.BRAF inhibition in BRAFV600E-positive anaplastic thyroid carcinoma[J].J Natl Compr Canc Netw，2016，14（3）：249-254.
[14]	Latteyer S，Tiedje V，Konig K，et al.Targeted next-generation sequencing for TP53，RAS，BRAF，ALK and NF1 mutations in anaplastic thyroid cancer[J].Endocrine，2016，54（3）：733-741.
[15]	Liu Z，Hou P，Ji M，et al.Hishly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways inanaplasticandfollicllarthyroidcancers[J].JClinEndocrinol Metab，2008，93（5）：3106-3116.
[16]	Zhang P，Wang C，Ma T，et al.O-GlcNAcylation enhances the invasion of thyroid anaplastic cancer cells partially by PI3K/Akt1 pathway[J].Onco Targets Ther，2015，8（1）：3305-3313.
[18]	SpitzwegC.Genetherapyinthyroidcancer[J].HormMetabRes，2009，41（6）：500-509.
[22]	Xing M.Molecular pathogenesis and mechanisms of thyroid.cancer[J].Nat Rev Cancer，2013，13（3）：184-199.
[26]	Miyamoto S.Nuclear initiated NF-κB signaling：NEMO and ATM take center stage[J].Cell Res，2011，21（3）：116-130.
[17]	Blagosklonny MV，Giannakakou P，Wojtowicz M，et al.Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells[J].J Clin Endocrinol Metab，1998，83（1）：2516-2522.
[19]	Soares P，Lima J，Preto A，et al.Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas[J]. Curt Genomies，2011，12（1）：609-617．
[20]	Mc Fadden DG，Vernon A，Santiago PM，et al.p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer[J].Proc Natl Acad Sci USA，2014，111（16）：E1600-E1609.
[21]	Garcia-Rostan G，Tallini G，Herrero A，et al.Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma[J].Cancer Res，1999，59（8）：1811-1815.
[23]	Kim HJ，Kim MJ，Kim A，et al.The role of notch 1 signaling in anaplastic thyroid carcinoma[J].Cancer Res Treat，2017，49（2）：509-517.
[24]	Ferretti E，Tosi E，Po A，et al.Notch signaling is involved inexpressionofthyrocytedifferentiationmarkersandisdownregulated in thyroid tumors[J].J Clin Endocrinol Metab，2008，93（10）：4080-4087.
[25]	Li J，Zheng X，Gao M，et al.Suberoyl bis-hydroxamic acid activates Notch 1 signaling and induces apoptosis in anaplas-tic thyroid carcinoma through p53[J].Oncol Rep，2017，37（3）：458-464.
[27]	Meng Z，Lou S，Tan J，et al.Nuclear factor-kappa B inhibition can enhance the rapeutic efficacy of131I on the in vivo management of differentiated thyroid cancer[J].Life Sci，2012，91（5）：1236-1241.
[28]	Yin Q，Liu S，Dong A，et al.Targeting transforming growth factor-beta1（TGF-beta1）inhibitstumorigenesisofanaplastic thyroid carcinoma cells through ERK1/2-NF kappa BPUMA signaling[J].Med Sci Monit，2016，22（1）：2267-2277.
[29]	Romei C，Elisei R.Ret/ptc translocations and clinico-pathological features in human papillary thyroid carcinoma[J]. Front Endocrinol（Lausanne），2012，（3）：54.
[30]	Kimura ET，Nikiforova MN，Zhu Z，et al.High prevalence of BRAF mutations in thyroid cancer：genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J].Cancer Res，2003，63（1）：1454-1457.
[31]	Greco A，Miranda C，Pierotti MA.Rearrangements of NTRK1 gene in papillary thyroid carcinoma[J].Mol Cell Endocrinol，2010，28，321（1）：44-49.
[32]	Antonelli A，Bocci G，Fallahi P，et al.CLM3，a multitarget tyrosine kinase inhibitor with antiangiogenic properties，is active against primary anaplastic thyroid cancer in vitro and in vivo[J].J Clin Endocrinol Metab，2014，99（1）：E572-E581.
[33]	Liu Z，Hou P，Ji M，et al.Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways inanaplasticandfollicularthyroidcancers[J].JClinEndocrinol Metab，2008，93（1）：3106-3116.